RegCell, ALS, and BIOSPAIN Shift
Kilder
- Endpoints: RegCell lands $44M Series A to take Nobel-winning Tregs into clinic
- Endpoints: Axoltis says its Phase 2 study for an experimental ALS drug failed
- European-biotechnology: Axoltis ALS drug misses Phase 2 endpoint - European Biotechnology Magazine
- Raps: Recon: Experts press FDA to set safety, access standards for psychedelic drugs; GSK to shut German vaccine factory due to low demand - RAPS
- Endpoints: Rocket's Danon plans; Novo leaves Ascendis; Lilly's latest deal
- STAT: STAT+: Obesity drugmakers are testing in kids as young as 6
- Ua: STAT News: obesity drugmakers are testing them in children as young as six - UA.NEWS
- Ua: Arab Parliament condemns Houthi attacks on Saudi Arabia — Asharq Al-Awsat - UA.NEWS
- Labiotech: BIOSPAIN 2026: Spain’s flagship biotech event is going annual
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.